Lupin Limited published its unaudited financial results for the quarter ended June 30, 2026, in newspapers on August 8, 2026, fulfilling its disclosure obligations under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This procedural step confirms the financial figures previously reported to stock exchanges, including a standalone net profit after tax (PAT) of ₹27,146 million and consolidated revenue from operations of ₹82,769 million. The publication ensures broader accessibility of the quarterly performance data for investors and stakeholders who rely on print media for regulatory updates.

The newspaper advertisement, signed by Company Secretary and Compliance Officer Amit Kumar Gupta, enclosed copies of the extract of the unaudited financial results. The underlying financial data had already been reviewed by the Audit Committee and approved by the Board of Directors at a meeting held on August 6, 2026. The results were subjected to a limited review by statutory auditors Deloitte Haskins & Sells Chartered Accountants LLP, in compliance with Regulation 33 of the SEBI LODR Regulations.

Financial Performance Recap

The published figures reiterate the strong growth trajectory observed in Q1FY26. Standalone sales/income from operations jumped 27% year-on-year to ₹71,125 million, while total revenue from operations reached ₹71,719 million. On a consolidated basis, total income stood at ₹84,072 million, compared to ₹63,474 million in the corresponding quarter last year. The Pharmaceuticals segment remained the primary driver, contributing ₹82,344 million to consolidated revenue.

Standalone basic earnings per share (EPS) increased to ₹59.37 from ₹46.60 in the previous year’s quarter. Consolidated basic EPS rose to ₹30.95 from ₹26.70. Other income for the standalone entity was ₹1,025 million, while consolidated other income stood at ₹1,303 million.

Key Developments and Segment Analysis

The Pharmaceuticals segment generated a result before tax and exceptional items of ₹20,606 million in the consolidated books, up significantly from ₹14,578 million in Q1FY25. This growth underscores the segment’s dominance in driving profitability. The 'Others' segment reported a loss of ₹432 million, consistent with its historical pattern of lower margins.

During the quarter, Lupin concluded the acquisition of wholly-owned subsidiary VISUfarma B.V., Netherlands, through Nanomi B.V. on April 1, 2026. The total consideration was ₹20,903 million (Euro 192.8 million). The fair value of intangibles acquired was ₹15,971 million, with goodwill provisionally accounted at ₹6,030 million based on an independent valuer’s report. Additionally, 53,425 equity shares were allotted upon the exercise of vested stock options under the Lupin Employees Stock Option Plans, increasing paid-up capital by ₹0.1 million and securities premium by ₹76.9 million.

What the Numbers Show

A notable divergence exists between standalone and consolidated profitability metrics. While standalone PAT grew by 27%, consolidated PAT growth was more modest at 16%. This gap is primarily attributable to higher tax expenses and integration costs associated with recent acquisitions, including VISUfarma. Furthermore, the group recognized an impairment charge of ₹879 million during the quarter related to certain capital work-in-progress and intangible assets under development. Despite these headwinds, the core pharmaceutical business demonstrated resilience, with revenue growth outpacing expense inflation, indicating strong operational leverage in key markets.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE326A01037/1aac2b5f-3efa-4ca1-bccf-95c778cfce32.pdf

Lupin Ltd. recorded a notable block trade on the National Stock Exchange (NSE), with the transaction valued at ₹29.03 crores. The deal involved approximately 1,21,534 shares, executed at a price of ₹2388.30 per share.

Block Trade Details

The following table summarizes the key parameters of the block trade:

Block trades are large, privately negotiated securities transactions that are executed outside of the open market to minimize the impact on the stock's prevailing price. Such transactions are generally associated with institutional investors or significant stakeholders, and their occurrence on major exchanges like the NSE is closely monitored by market participants.